News

ALKS 3831 is composed of samidorphan, a new, potent mu-opioid antagonist, in combination with an antipsychotic drug, olanzapine. The trial is designed to evaluate the efficacy, safety and

Chimerix received the initial award in February 2011 which supported early research and development of brincidofovir in animal models of smallpox (Contract Number HHSO100201100013C). This contract extension provides

Orphan is a privately-held, Toronto-based specialty pharmaceutical company that in-licenses therapies for rare disorders and specialty medicines for the Canadian market. As part of the agreement, Jason Flowerday

The US Food and Drug Administration (FDA) has recently approved Northera to treat NOH, a disorder caused by an underlying neurologic disease. Currently, the norepinephrine pro-drug Northera is

Both SLE and LN represent an area of high unmet medical need, where new therapies are essential. SLE is an autoimmune disease, where the immune system produces proteins

CureXcell is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. A total of 280 patients

The Covance Antibody business unit develops and manufactures antibodies and research reagents for Neuroscience, Immunopathology, Cell Biology, Epitope Tags, and Immunohistochemistry Detection. These products, including In Vitro Diagnostic

"Inflammation in old age can have significant consequences on immune function," said Joanne Turner, Ph.D., a researcher involved in the work from the Department of Microbial Infection and

"In light of the promising Knee Osteoarthritis Phase IIa six month follow-up results we decided to explore the efficacy of our proprietary ReJoinTM therapy on an additional orthopedic